---
title: "Bristol-Myers Squibb (United Kingdom): research papers"
description: "From 2017 to 2026 (so far), authors at Bristol-Myers Squibb (United Kingdom) took part in 30 papers in the tracked journals, most of them in health economics and policy (29) and statistics (1). 3 of them were published in 2025, against 2 in 2017."
url: https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom
markdown_url: https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom.md
license: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
share_text: "From 2017 to 2026 (so far), authors at Bristol-Myers Squibb (United Kingdom) took part in 30 papers in the tracked journals, most of them in health economics and policy (29) and statistics (1). 3 of them were published… (as of 2026-10-31)"
data_url: https://scholar4ai.com/data/rankings.json
updated: 2026-10-31T19:11:11+09:00
window: 2026-10-02 to 2026-10-31
source: OpenAlex (CC0)
---

# Bristol-Myers Squibb (United Kingdom)

Papers in the tracked journals with an author at Bristol-Myers Squibb (United Kingdom): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education.

Back to the ranking: https://scholar4ai.com/rankings/companies.md

## Key findings

- From 2017 to 2026 (so far), authors at Bristol-Myers Squibb (United Kingdom) took part in 30 papers in the tracked journals, most of them in health economics and policy (29) and statistics (1).
- 3 of them were published in 2025, against 2 in 2017.
- Since 2023, the institutions with the most of these papers were Bristol-Myers Squibb (United States) (12), Bristol-Myers Squibb (France) (2) and University College London (2).
- The journals publishing most of them were PharmacoEconomics - Open (9), PharmacoEconomics (3) and The European Journal of Health Economics (2).
- The most-cited of them is “Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models” (PharmacoEconomics - Open, 2024), with 71 citations.
- Since 2023, papers in the tracked journals cited 16 of its papers 34 times; 82% of those links came from papers with a university author and 21% from its own papers.
- Its own papers since 2023 cite archived papers 30 times, 57% of them papers with a company author.

## Papers per year

*Papers per publication year and category*

| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| [Health Economics and Policy](https://scholar4ai.com/categories/health-economics-and-policy.md) | 2 | 4 | 3 | 1 | 3 | 2 | 3 | 7 | 3 | 1 |
| [Statistics](https://scholar4ai.com/categories/statistics.md) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| All categories | 2 | 4 | 3 | 1 | 3 | 2 | 3 | 8 | 3 | 1 |

## Where the papers come from

*Journals with the most papers, since 2023*

| # | Journal | Papers |
|---:|---|---:|
| 1 | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 9 |
| 2 | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 3 |
| 3 | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 2 |
| 4 | [Journal of Statistical Planning and Inference](https://scholar4ai.com/journals/journal-of-statistical-planning-and-inference.md) | 1 |

*Institutions with the most papers, since 2023*

| # | Institution | Papers |
|---:|---|---:|
| 1 | Bristol-Myers Squibb (United States) | 12 |
| 2 | Bristol-Myers Squibb (France) | 2 |
| 3 | University College London | 2 |
| 4 | University of Glasgow | 2 |
| 5 | University of Sheffield | 2 |
| 6 | Adelphi Group (United Kingdom) | 1 |
| 7 | Bristol-Myers Squibb (Sweden) | 1 |
| 8 | Bristol-Myers Squibb (Switzerland) | 1 |
| 9 | [Centre National de la Recherche Scientifique](https://scholar4ai.com/institutions/centre-national-de-la-recherche-scientifique.md) | 1 |

*Countries with the most papers, since 2023*

| # | Country | Papers |
|---:|---|---:|
| 1 | United Kingdom | 15 |
| 2 | United States | 12 |
| 3 | France | 2 |
| 4 | Switzerland | 1 |
| 5 | China | 1 |
| 6 | Denmark | 1 |
| 7 | Sweden | 1 |

*Keywords with the most papers, since 2023*

| # | Keyword | Papers |
|---:|---|---:|
| 1 | [cost-effectiveness](https://scholar4ai.com/keywords/cost-effectiveness.md) | 6 |
| 2 | quality-adjusted life years | 5 |
| 3 | health care costs | 3 |
| 4 | health technology assessment | 3 |
| 5 | immune checkpoint inhibitors | 3 |
| 6 | [large language models](https://scholar4ai.com/keywords/large-language-models.md) | 3 |
| 7 | nivolumab | 3 |
| 8 | GPT-4 | 2 |
| 9 | atrial fibrillation | 2 |
| 10 | cancer immunotherapy | 2 |

## Most-cited papers

*Most-cited papers since 2017*

| # | Citations | Per month | Title | Journal | Published | Authors |
|---:|---:|---:|---|---|---|---|
| 1 | 71 | 2.2 | [Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models](https://doi.org/10.1007/s41669-024-00476-9) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2024-02-10 | Tim Reason, Emma Benbow, Julia Langham et al. |
| 2 | 65 | 0.6 | [Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation](https://doi.org/10.1007/s40273-017-0558-5) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2017-09-02 | Eddie Gibson, Ian Koblbauer, Najida Begum et al. |
| 3 | 41 | 1.3 | [Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language Models](https://doi.org/10.1007/s41669-024-00477-8) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2024-02-10 | Tim Reason, William D. Rawlinson, Julia Langham et al. |
| 4 | 32 | 0.3 | [The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England](https://doi.org/10.1007/s10198-018-0964-4) | [The European Journal of Health Economics](https://scholar4ai.com/journals/the-european-journal-of-health-economics.md) | 2018-03-09 | Yang Meng, Nadine Hertel, J. Ellis et al. |
| 5 | 27 | 0.3 | [An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?](https://doi.org/10.1016/j.healthpol.2018.04.008) | [Health Policy](https://scholar4ai.com/journals/health-policy.md) | 2018-04-26 | Jason T. Shafrin, Michelle Skornicki, Michelle Brauer et al. |
| 6 | 27 | 0.4 | [What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma](https://doi.org/10.1007/s40273-020-00989-1) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2021-01-11 | Sven L. Klijn, Elisabeth A. L. Fenwick, Sonja Kroep et al. |
| 7 | 24 | 0.3 | [Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England](https://doi.org/10.1007/s41669-020-00245-4) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2020-12-17 | Ben Rothwell, Christopher Kiff, Caroline S. Ling et al. |
| 8 | 21 | 0.3 | [A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity](https://doi.org/10.1007/s40273-019-00867-5) | [PharmacoEconomics](https://scholar4ai.com/journals/pharmacoeconomics.md) | 2019-12-17 | Tim S. Grant, Darren K. Burns, Christopher Kiff et al. |
| 9 | 20 | 0.2 | [Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England](https://doi.org/10.1007/s41669-018-0080-5) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2018-05-22 | Dawn Lee, A. Amadi, Javier Sabater et al. |
| 10 | 19 | 1.1 | [Using Generative Artificial Intelligence in Health Economics and Outcomes Research: A Primer on Techniques and Breakthroughs](https://doi.org/10.1007/s41669-025-00580-4) | [PharmacoEconomics - Open](https://scholar4ai.com/journals/pharmacoeconomics-open.md) | 2025-04-29 | Tim Reason, Sven L. Klijn, William D. Rawlinson et al. |

## Who cites its research

*Institutions whose papers cite it most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | [Bristol-Myers Squibb (United States)](https://scholar4ai.com/companies/bristol-myers-squibb-united-states.md) | Company | United States | 7 |
| 2 | China Pharmaceutical University | University | China | 4 |
| 3 | University of Sheffield | University | United Kingdom | 4 |
| 4 | AstraZeneca (United Kingdom) | Company | United Kingdom | 3 |
| 5 | Tulane University | University | United States | 3 |
| 6 | University of York | University | United Kingdom | 3 |
| 7 | Erasmus University Rotterdam | University | Netherlands | 3 |
| 8 | Brigham and Women's Hospital | Healthcare | United States | 2 |
| 9 | Harvard University | University | United States | 2 |

## What its papers cite

*Institutions its papers cite most, since 2023*

| # | Institution | Kind | Country | Links |
|---:|---|---|---|---:|
| 1 | University of Sheffield | University | United Kingdom | 8 |
| 2 | [Bristol-Myers Squibb (United States)](https://scholar4ai.com/companies/bristol-myers-squibb-united-states.md) | Company | United States | 6 |
| 3 | Memorial Sloan Kettering Cancer Center | Healthcare | United States | 3 |
| 4 | AstraZeneca (Sweden) | Company | Sweden | 3 |
| 5 | AstraZeneca (United States) | Company | United States | 3 |
| 6 | University of Glasgow | University | United Kingdom | 3 |
| 7 | École Supérieure des Sciences Économiques et Commerciales | Other | France | 2 |
| 8 | University of Leicester | University | United Kingdom | 2 |
| 9 | EuroQol Research Foundation | Nonprofit | Netherlands | 2 |

More: https://scholar4ai.com/corporate-citations.md · https://scholar4ai.com/industry-university.md

## Cite this page

Scholar4AI. (2026). Bristol-Myers Squibb (United Kingdom). Journal Research Rankings. Retrieved October 31, 2026, from https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom

```bibtex
@misc{scholar4ai-companies-bristol-myers-squibb-united-kingdom,
  author = {{Scholar4AI}},
  title = {Bristol-Myers Squibb (United Kingdom)},
  year = {2026},
  howpublished = {\url{https://scholar4ai.com/companies/bristol-myers-squibb-united-kingdom}},
  urldate = {2026-10-31},
  note = {Journal Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}
```

License: CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/).